Immunotherapy strategies across bladder cancer continuum

Apolo highlighted the positive topline results from the phase 3 EV-303 trial (NCT03924895) evaluating EV plus pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer.

Christof Vulsteke, MD, PhD, discusses results from the KEYNOTE-905 trial, evaluating perioperative EV/pembrolizumab in cisplatin-ineligible MIBC.

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025.

Joshua J. Meeks, MD, PhD, highlights that collaboration between urologists and medical oncologists has become essential.

One particularly striking finding from KEYNOTE-905/EV-303 is the nearly 60% pathologic complete response rate.

At the 2025 LUGPA Annual Meeting, Joshua J. Meeks, MD, PhD, outlined the rapidly evolving treatment landscape in MIBC.